[1]Pascual B, Prieto E,Arbizu J, et al. Decreased carbon-11-flumazenil binding in early Alzheimer’s disease[J]. Brain, 2012, 135(9): 2817-2825.
[2]Caroline P, Funck T, Sidel M, et al. Up-Regulation of GABA-A receptors in parkinson’s disease with dyskinesias[J]. Ann Neurol, 2014, 76(Sup): S49-S49.
[3]Luchetti S, Huitinga I, Swaab D F, et al. Neurosteroid and GABA-A receptor alterrations in alzheimer’sdisease, Parkinson’s disease and multiple sclerosis[J]. Neurosci, 2011, 191: 6-21.
[4]Asahina N,Shiga T,Egawa K, et al. [11C]Flumazenil positron emission tomography analyses of brain gamma-aminobutyric acid type a receptors in angelman syndrome[J]. J Pediatr, 2008, 152(4): 1-3.
[5]Njiwa J Y, bouvard S, Catenoix H, et al. Periventricular [11C]flumazenil binding for predicting postoperative outcome in patients with temporal lobe epilepsy and hippocampal sclerosis[J]. NeuroImage: Clinicl, 2013, 3(8): 242-248.
[6]Hesis W D, Kracht L W, Crond M, et al. [11C]Flumazenil/H2O positron emission tomography predicts irreversible ischemic cortical damage in stroke patients receiving acute thrombolytic therapy[J]. Stroke, 2000, 31(2): 366-369.
[7]Hesis W D, Kracht L W, Thiel A, et al. Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia[J]. Brain, 2001, 124(1): 20-29.
[8]Salmi E, Aalto S, Hirvonen J, et al. Meassurement of GABA-A receptor binding in vivo with [11C]-flumazenil: A test-retest study in healthy subjects[J]. NeuroImage, 2008, 41(2): 260-269.
[9]Syvanen S, Delange E C,Tagawa Y, et al. Simutaneous in vivo meassurements of density and affinity using [11C]flumazenil and positron emission tomography:Comparison of full saturation and steady state methods[J]. Neuro Image, 2011, 57(3): 928-937.
[10]Maziere M, Hantraye P, Prenant C, et al. Synthesis of ethyl 8-fluoro-5,6-dihydro-5-[11C]methyl-6-oxo-4H-imidazol [1,5-a][1,4]benzodiazepine-3-carboxylate(RO 15. 1788-11C)[J]. Int J Appl Radiat Isot, 1984, 35(10): 973-976.
[11]Cleij M C, Clank J C, Baron J C, et al. Rapid preparation of [11C]flumazenil: Captive solvent synthesis combined with purification by analytical sized columns[J]. J Label Compd Radiopharm, 2007, 50(1): 19-24.
[12]Krasikova R, Fedorova O, Korsakov M, et al. A fast and convenient method for preparation of [11C] flumazenil avoiding HPLC purification[J]. J labelled Cpd Radiopharm, 2000, 43(6): 613-621.
[13]Baldwin B M, Horti A G, Bremner J D, et al. Synthesis and PET imaging of the benzodiazepine receptor tracer [N-Methyl-11C]iomazenil[J]. Nucl Med Biol, 1995, 22(5): 659-665.
[14]Noguchi J, Suzuki K. Automated synthesis of the ultra high specific activity of [11C]Ro15-4513 and its application in an extremely low concentration region to an ARG study[J]. Nucl Med Bio, 2003, 30(3): 335-343. |